Factor H is the major soluble inhibitor of complement, where its binding to self markers (i.e., particular glycan structures) prevents complement activation and amplification on host surfaces. Not surprisingly, mutations and polymorphisms that affect recognition of self by factor H are associated with diseases of complement dysregulation, such as age-related macular degeneration and atypical haemolytic uremic syndrome. In addition, pathogens (i.e., non-self) and cancer cells (i.e., altered-self) can hijack factor H to evade the immune response.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 μg | 5 days | $ 418.00 | |
500 μg | 5 days | $ 1,670.00 | |
1 mg | 5 days | $ 2,800.00 |
Description | Factor H is the major soluble inhibitor of complement, where its binding to self markers (i.e., particular glycan structures) prevents complement activation and amplification on host surfaces. Not surprisingly, mutations and polymorphisms that affect recognition of self by factor H are associated with diseases of complement dysregulation, such as age-related macular degeneration and atypical haemolytic uremic syndrome. In addition, pathogens (i.e., non-self) and cancer cells (i.e., altered-self) can hijack factor H to evade the immune response. |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Accession Number | P08603-1 |
Synonyms | ARMD4, AHUS1, H factor 1, HF1, AMBP1, FH, FHL1, HUS, CFHL3, ARMS1, HF2, Complement factor H, HF, CFH |
Construction | Recombinant Human Factor H/CFH Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Ser860-Arg1231.[Accession |P08603-1] |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Molecular Weight | The protein has a predicted MW of 42.8 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Tris-Bis PAGE result. |
Endotoxin | Less than 1EU per μg by the LAL method. |
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Stability & Storage |
-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping |
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
Research Background | Factor H is the major soluble inhibitor of complement, where its binding to self markers (i.e., particular glycan structures) prevents complement activation and amplification on host surfaces. Not surprisingly, mutations and polymorphisms that affect recognition of self by factor H are associated with diseases of complement dysregulation, such as age-related macular degeneration and atypical haemolytic uremic syndrome. In addition, pathogens (i.e., non-self) and cancer cells (i.e., altered-self) can hijack factor H to evade the immune response. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
Complement factor H/CFH Protein, Human, Recombinant (His) AMBP 1 AMBP-1 ARMD4 HF 2 FHL-1 AHUS 1 CFHL-3 ARMD-4 AHUS1 H factor 1 AHUS-1 HF-2 HF-1 HF1 ARMS 1 AMBP1 FH FHL1 ARMS-1 HUS CFHL3 ARMS1 CFHL 3 HF 1 ARMD 4 HF2 Complement factor H FHL 1 HF CFH recombinant recombinant-proteins proteins protein